Suven Life Sciences Ltd

Suven Life Sciences Ltd Share Price Today: Live Updates & Key Insights

Get insights on Suven Life Sciences Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Suven Life Sciences Ltd Share Price Chart

Suven Life Sciences Ltd Fundamentals

Traded Volume: 2,07,768

Market Cap(Cr): 4,315

Avg Traded Price 29.13

1 Year return 41.50%

Upper Circuit 195

Lower Circuit 188

P/E TTM -23.00

P/B Ratio -8.00

Traded Value(Cr) 394.09

EPS TTM -8.099

Book value -8.099

Dividend 0.00%

Suven Life Sciences Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Suven Life Sciences Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Suven Life Sciences Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -1.46%

1M -9.42%

3M -25.63%

1Y +41.50%

YTD +50.74%

Suven Life Sciences Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Suven Life Sciences Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.19L

Day Before Yesterday 93051.00

1W Avg 1.31L

1M Avg 1.51L

3M Avg 1.55L

Suven Life Sciences Ltd Technical Details

Suven Life Sciences Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 187

Support 2 184

Support 3 180

Pivot Point : 191

Resistance 1 194

Resistance 2 198

Resistance 3 201

Suven Life Sciences Ltd Corporate Actions

Suven Life Sciences Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Suven Life Sciences Ltd’s capital allocation strategies.

All

Ex-Date 17-Oct-2022 Type R Description /share@1:2% Record Date 18-Oct-2022 Ratio 1:2

Ex-Date 14-Feb-2019 Type D Description 1.50/share@150.00% Record Date 15-Feb-2019 Ratio 150.00

Ex-Date 06-Feb-2018 Type D Description 1.50/share@150.00% Record Date 07-Feb-2018 Ratio 150.00

Ex-Date 08-Feb-2017 Type D Description 1.00/share@100.00% Record Date 09-Feb-2017 Ratio 100.00

Ex-Date 14-Mar-2016 Type D Description 1.00/share@100.00% Record Date 15-Mar-2016 Ratio 100.00

Ex-Date 14-Mar-2016 Type D Description 1.00/share@100.00% Record Date 15-Mar-2016 Ratio 100.00

Ex-Date 23-Jul-2015 Type D Description 0.60/share@60.00% Record Date 07-Nov-2025 Ratio 60.00

Ex-Date 24-Jul-2014 Type D Description 2.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00

Ex-Date 24-Jul-2014 Type D Description 0.50/share@50.00% Record Date 07-Nov-2025 Ratio 50.00

Ex-Date 01-Aug-2013 Type D Description 0.30/share@30.00% Record Date 07-Nov-2025 Ratio 30.00

Ex-Date 17-Sep-2012 Type D Description 0.30/share@30.00% Record Date 07-Nov-2025 Ratio 30.00

Ex-Date 01-Aug-2011 Type D Description 0.25/share@25.00% Record Date 07-Nov-2025 Ratio 25.00

Ex-Date 19-Jul-2010 Type D Description 0.25/share@25.00% Record Date 07-Nov-2025 Ratio 25.00

Ex-Date 14-Sep-2009 Type D Description 0.25/share@25.00% Record Date 07-Nov-2025 Ratio 25.00

Ex-Date 11-Sep-2008 Type D Description 0.25/share@25.00% Record Date 07-Nov-2025 Ratio 25.00

Ex-Date 21-Sep-2007 Type D Description 0.25/share@25.00% Record Date 07-Nov-2025 Ratio 25.00

Ex-Date 23-Mar-2007 Type S Description share@1:2.00 Record Date 02-Apr-2007 Ratio 1:2.00

Ex-Date 23-Mar-2007 Type B Description share@1:1 Record Date 02-Apr-2007 Ratio 1:1

Dividends

Announcement Date 14-Feb-2019 Ex Dividend Date 14-Feb-2019 Dividend(%) 150

Announcement Date 06-Feb-2018 Ex Dividend Date 06-Feb-2018 Dividend(%) 150

Announcement Date 08-Feb-2017 Ex Dividend Date 08-Feb-2017 Dividend(%) 100

Announcement Date 14-Mar-2016 Ex Dividend Date 14-Mar-2016 Dividend(%) 100

Announcement Date 14-Mar-2016 Ex Dividend Date 14-Mar-2016 Dividend(%) 100

Announcement Date 23-Jul-2015 Ex Dividend Date 23-Jul-2015 Dividend(%) 60

Announcement Date 24-Jul-2014 Ex Dividend Date 24-Jul-2014 Dividend(%) 200

Announcement Date 24-Jul-2014 Ex Dividend Date 24-Jul-2014 Dividend(%) 50

Announcement Date 01-Aug-2013 Ex Dividend Date 01-Aug-2013 Dividend(%) 30

Announcement Date 17-Sep-2012 Ex Dividend Date 17-Sep-2012 Dividend(%) 30

Announcement Date 01-Aug-2011 Ex Dividend Date 01-Aug-2011 Dividend(%) 25

Announcement Date 19-Jul-2010 Ex Dividend Date 19-Jul-2010 Dividend(%) 25

Announcement Date 14-Sep-2009 Ex Dividend Date 14-Sep-2009 Dividend(%) 25

Announcement Date 11-Sep-2008 Ex Dividend Date 11-Sep-2008 Dividend(%) 25

Announcement Date 21-Sep-2007 Ex Dividend Date 21-Sep-2007 Dividend(%) 25

Bonus

Record Date 02-Apr-2007 Ex-Bonus Date 23-Mar-2007 Ratio 1:1

Splits

Record Date 02-Apr-2007 Split Date 23-Mar-2007 Face Value (Before/After) 2.00/1.00

Others

Ex-Rights Date 17-Oct-2022 Premium(Rs.) 54.00 Ratio 1:2

Suven Life Sciences Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Suven Life Sciences Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Suven Life Sciences Ltd's relative performance and valuation against major competitors.

Stock Name Thyrocare Technologies Ltd ₹1391.10 (+5.05%) M. Cap (Cr) 73.80 1 Yr Return (%) +43.77% P/E (TTM) 57.78 PB Ratio 15.12

Stock Name Kovai Medical Center & Hospital Ltd ₹2576.65 (-2.28%) M. Cap (Cr) 28.19 1 Yr Return (%) +68.20% P/E (TTM) 30.73 PB Ratio 6.24

Stock Name Entero Healthcare Solutions Ltd ₹1089.30 (+3.00%) M. Cap (Cr) 47.39 1 Yr Return (%) -25.06% P/E (TTM) 46.22 PB Ratio 2.82

Stock Name Suven Life Sciences Ltd ₹189.68 (-1.63%) M. Cap (Cr) 43.15 1 Yr Return (%) +41.50% P/E (TTM) -23.42 PB Ratio 38.90

Stock Name Medi Assist Healthcare Services Ltd ₹493.80 (-3.66%) M. Cap (Cr) 36.72 1 Yr Return (%) -20.69% P/E (TTM) 45.12 PB Ratio 7.49

Stock Name Vimta Labs Ltd ₹657.80 (+5.77%) M. Cap (Cr) 29.30 1 Yr Return (%) +124.98% P/E (TTM) 37.49 PB Ratio 7.73

Stock Name Krsnaa Diagnostics Ltd ₹724.30 (-3.86%) M. Cap (Cr) 23.50 1 Yr Return (%) -21.91% P/E (TTM) 29.29 PB Ratio 2.79

Suven Life Sciences Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Suven Life Sciences Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 -47.39 Mar 2024 -20.56 Mar 2023 -10.09 Mar 2022 -36.62 Mar 2021 -36.68

PARTICULARS Investing Activities Mar 2025 44.21 Mar 2024 -0.68 Mar 2023 -361.66 Mar 2022 -107.46 Mar 2021 2.41

PARTICULARS Financing Activities Mar 2025 -0.76 Mar 2024 -1.05 Mar 2023 395.54 Mar 2022 145.69 Mar 2021 34.86

PARTICULARS Net Cash Flow Mar 2025 -3.94 Mar 2024 -22.30 Mar 2023 23.79 Mar 2022 1.61 Mar 2021 0.58

Suven Life Sciences Ltd Shareholding Pattern

This shows the ownership breakdown of Suven Life Sciences Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 67.36%

Public 28.07%

Other Institutions 1.31%

FII 1.17%

Mutual Funds 2.08%

About Suven Life Sciences Ltd

Suven Life Sciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated in March, 1989. The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003. Promoted by Venkateswarlu Jasti, Company began its operations in 1989 as specialty chemicals provider.The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies.The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors. Suven's CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business.In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. During 1999-2000, the company acquired a small pilot plant in Jeedimetla Industrial Estate, Hyderabad.During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 have registered a growth of 71% over the previous year. The Profit After Tax (PAT) has also registered a growth of 325% over the previous year.During the financial year ended 31 March 2014, Suven's Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition, D-4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 2014-15.During the year 2014, Suven has made significant inroads into drug discovery with a specialization on CNS-based programmes targeting unmet medical needs. The Company enjoys a unique position in the India (and Asia) as one of the prominent company with technologies under central nervous system (CNS). It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suven's discovery assets address niche therapeutic areas like cognition, depression, obesity and pain management.In FY14, the Company filed one ANDA with the USFDA authorities for Malathion lotion, a head-lice product with sales potential estimated at US$35 million. In 2013-14, it granted the exclusive license to Taro Pharmaceuticals to market the product in the US, Canada and Mexico, which is expected to generate revenues and royalty in 2014-15. During FY2015, Suven's lead clinical candidate SUVN-502 has successfully completed Phase 1b clinical trial thus paving the way for the co-pound to move into Proof of Concept (PoC) Phase 2a study. In addition to above compounds, SUVN D-4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA.During the FY2015, the Company has issued and allotted 104,53,690 equity shares of Re 1/- each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines.During FY15, the Company's main focus stayed on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. During FY15, the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient.During FY2017, the company has spent Rs. 6973 lakhs on innovative R&D in CNS therapies accounting for 13% on sales. Its focus remained on discovering, developing and commercializing novel pharmaceutical products, which are first in class CNS therapies through use of GPCR targets. During FY 2017, the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc., a wholly owned subsidiary, for its business purpose.In FY2018, the company has spent Rs 6,390 lakhs on innovative R&D in CNS therapies accounting for 10% on sales.The Company invested a sum of Rs.13,636 lakhs in Suven Neurosciences, Inc., for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement (Demerger) and as of 31st March, 2019 no investments were made in newly formed Suven Pharma, Inc. in USA.During the FY 2018-2019, Suven Pharmaceuticals Limited in India and Suven Pharma, Inc., in USA became the subsidiary companies.In 2018-19, the Company completed the Clinical Trial (Phase II) of the lead molecule SUVN-502, Masupirdine. In 2019-20, the Contract Research and Manufacturing Services (CRAMS) Undertaking of the Company was demerged to its wholly owned subsidiary, Suven Pharmaceuticals Limited as a going concern through a Scheme of Arrangement effective from 1st October, 2018.In FY 2025, SUVN-I6107 launched for the treatment of cognitive impairment associated with neurodegenerative disorders. The scale-up of two lead-like compounds has been completed to support additional efficacy and safety profiling. It commissioned Serotonin and dopamine modulator for psychiatric disorders during the year. Suven engaged with the FDA to seek guidance on the design of the Phase 2 study for Usmarapride in 2025. The Company initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical trials for the investigational compound SUVN-G3031.

Chairman & Chief Executive Officer

Venkateswarlu Jasti

Registered office #8-2-334 SDE Serene Chambers, 6 th Floor Road No 5 Avenue 7, Hyderabad, Telangana, 500034

FAX :91-40-23541142/3311/3315

Background

Incorporation Year 1989

Face Value ₹1.00

Market Lot 1

Suven Life Sciences Ltd Latest News

VIEW MORE NEWS

FAQs on Suven Life Sciences Ltd